Comparative Effectiveness of Ivabradine versus Digoxin in Patients with Heart Failure with Reduced Ejection Fraction and Chronic Kidney Disease: A Real-World Multicenter Cohort Study
Vergleichende Wirksamkeit von Ivabradin versus Digoxin bei Patient:innen mit Herzinsuffizienz mit reduzierter Ejektionsfraktion und chronischer Nierenerkrankung: multizentrische Real-World-Kohortenstudie
Cardiorenal Medicine · 21.03.2026 · 16 (1) · 190-200
DOI: 10.1159/000551617 ↗Auf einen Blick
Bei Patient:innen mit HFrEF und CKD war Ivabradin mit einem geringeren Risiko für MACE verbunden als Digoxin. Auch HFE und Gesamtsterblichkeit traten seltener auf.
Fragestellung
Ist Ivabradin bei Patient:innen mit HFrEF und CKD mit einem geringeren Risiko für MACE als Digoxin verbunden?
Methode
Retrospektive Kohortenstudie mit Propensity-Score-Matching 1:1 in TriNetX; Erwachsene mit HFrEF und CKD zwischen 2015 und 2025; Cox-Modelle mit 95 %-KI.
Ergebnisse
3.140 Patient:innen (1.570 je Gruppe). MACE: 26,8 % vs. 31,6 %; HR 0,79 (95 %-KI 0,70–0,90; p < 0,001). HFE: HR 0,83 (95 %-KI 0,72–0,97). Mortalität: HR 0,69 (95 %-KI 0,56–0,85).
Schlussfolgerung der Autor:innen
In dieser großen Real-World-Kohorte war Ivabradin mit niedrigeren Risiken für MACE, HFE und Gesamtsterblichkeit verbunden als Digoxin.
Kernaussagen
- MACE unter Ivabradin seltener als unter Digoxin
- HFE und Gesamtsterblichkeit ebenfalls reduziert
- Retrospektive Kohortenstudie mit Propensity-Score-Matching
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Multizentrische Studie in der Zeitschrift Cardiorenal Medicine, online erschienen am 21.03.2026. Verfasst von Jheng-Yan Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition, Chi Mei Medical Centre, Tainan, Taiwan. Hauptthemen laut MEDLINE: Digoxin, Heart Failure, Ivabradine, Stroke Volume. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Introduction
Heart failure with reduced ejection fraction (HFrEF) commonly coexists with chronic kidney disease (CKD), conferring a markedly increased risk of adverse outcomes. Ivabradine and digoxin are both used for heart rate control in HFrEF, but their comparative effectiveness in patients with CKD remains uncertain. Therefore, this study aimed to compare the risk of major adverse cardiovascular events (MACE), including heart failure exacerbation (HFE) and all-cause mortality, between ivabradine and digoxin in patients with concomitant HFrEF and CKD.
Methods
Using the TriNetX global research network, we conducted a retrospective cohort study including adults with HFrEF and CKD between 2015 and 2025. Patients prescribed ivabradine were propensity score-matched 1:1 to those receiving digoxin based on demographic, clinical, laboratory, and medication variables. The primary outcome was MACE (composite of HFE or all-cause mortality). Secondary outcomes included each component separately. Cox proportional hazards models estimated hazard ratios (HRs) with 95% confidence intervals (CIs).
Results
After matching, 3,140 patients were included (1,570 per group). Ivabradine use was associated with a significantly lower risk of MACE compared with digoxin (26.8% vs. 31.6%; HR: 0.79, 95% CI: 0.70–0.90; p < 0.001). Ivabradine also reduced the risk of HFE (HR: 0.83, 95% CI: 0.72–0.97; p = 0.015) and all-cause mortality (HR: 0.69, 95% CI: 0.56–0.85; p < 0.001). Subgroup and negative-control analyses yielded consistent results.
Conclusions
In this large, real-world cohort of patients with HFrEF and CKD, ivabradine was associated with lower risks of MACE, HFE, and all-cause mortality compared with digoxin. Ivabradine may represent a safer and more effective heart rate-lowering option for this high-risk population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutrition, Chi Mei Medical Centre, Tainan, Taiwan.
- Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Centre, Chiali, Tainan, Taiwan.
- Department of Medical Education, Chi Mei Medical Centre, Tainan, Taiwan.
- Division of Hepatogastroenterology, Department of Internal Medicine, Chi Mei Medical Centre, Tainan, Taiwan, xxpil305a@gmail.com.
- Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Centre, Tainan, Taiwan, xxpil305a@gmail.com.
Zitieren
APA
Wu, J. Y., Lee, K. W., Huang, S. C., Chang, H. Y., & Lin, Y. M. (2026). Comparative Effectiveness of Ivabradine versus Digoxin in Patients with Heart Failure with Reduced Ejection Fraction and Chronic Kidney Disease: A Real-World Multicenter Cohort Study. Cardiorenal Medicine, 16(1), 190-200. https://doi.org/10.1159/000551617
Vancouver
Wu JY, Lee KW, Huang SC, Chang HY, Lin YM. Comparative Effectiveness of Ivabradine versus Digoxin in Patients with Heart Failure with Reduced Ejection Fraction and Chronic Kidney Disease: A Real-World Multicenter Cohort Study. Cardiorenal Medicine. 2026;16(1):190-200. doi:10.1159/000551617
BibTeX
@article{Wu2026,
author = {Wu, Jheng-Yan and Lee, Keng-Wei and Huang, Sheng-Chi and Chang, Hsuan-Yuan and Lin, Yu-Min},
title = {Comparative Effectiveness of Ivabradine versus Digoxin in Patients with Heart Failure with Reduced Ejection Fraction and Chronic Kidney Disease: A Real-World Multicenter Cohort Study},
journal = {Cardiorenal Medicine},
year = {2026},
volume = {16},
number = {1},
pages = {190--200},
doi = {10.1159/000551617}
}
EUVIMED